Our Story
How we began and where we're headed
Founded in 2014
Cena Research Institute was founded in 2014 in Houston, Texas, by Dr. Asif Ali, MD, with a vision to transform cardiovascular research through inclusive clinical trials and innovative med-tech validation.
Our Purpose
CRI operates as a bridge between academia, innovation, and underrepresented patient populations. We are not a conventional Clinical Research Organization. Under Dr. Ali's leadership, CRI functions as:
- A clinical innovation engine advancing the future of cardiovascular research
- A testing ground for AI-integrated and digitally enabled therapeutics
- A research equity champion creating space for underserved voices in trials
- A network node within AHA, public health circles, and startup ecosystems
Strategic Positioning
CRI distinguishes itself from traditional CROs through our unique approach:
Inclusive Focus
While traditional CROs often struggle with diversity in clinical trials, CRI actively engages diverse communities typically underrepresented in randomized controlled trials. We design studies that are accessible and meaningful to all patients.
Tech Validation Leadership
CRI is at the forefront of validating emerging medical technologies—AI, VR, wearables, and digital therapeutics. While traditional CROs are just beginning to explore these areas, CRI has been conducting trials in these spaces for years.
Academic-Industry Bridge
We connect research institutions with industry innovation, facilitating the translation of academic research into real-world health solutions. This bridge-building role is central to our mission.
Founder-Led Leadership
Dr. Asif Ali's direct involvement in research direction and execution ensures that CRI maintains its mission-driven focus. Unlike corporate CROs, our leadership is hands-on and committed to the research we conduct.
Public Patient Trust
CRI has built strong relationships with underserved and post-COVID populations, earning trust through our commitment to inclusive research and patient-centered care.
Looking Forward
As we continue to grow and expand our research capabilities, CRI remains committed to our founding mission: advancing cardiovascular research through inclusive, innovative, and impactful clinical trials. We are building a future where clinical research serves all patients, where emerging technologies are validated with diverse populations, and where innovation meets equity.